Salivary Metabolomics Found 65 Cannabis-Responsive Biomarkers in Children With Autism Treated With Medical Cannabis | Research

The takeaway

Using metabolomics analysis of saliva from 15 ASD children on individualized medical cannabis, 65 potential biomarkers shifted toward typically developing levels, including markers linked to inflammation, neurotransmitters, and endocannabinoids.

ASD researchers, metabolomics scientists, pediatric cannabis clinicians, precision medicine researchers.

65 salivary metabolite biomarkers responded to cannabis treatment in ASD children

What the researchers found

65 potential cannabis-responsive biomarkers shifted toward TD physiological levels in ASD children after medical cannabis treatment. 23 were categorized as anti-inflammatory, bioenergy-associated, neurotransmitters, amino acids, and endocannabinoids. N-acetylaspartic acid, spermine, and dehydroisoandrosterone 3-sulfate changes were particularly notable as they have been previously linked to ASD behavioral symptoms.

Why it matters

Developing objective biomarkers for ASD treatment response has been a longstanding challenge. This metabolomics approach could enable precision dosing and treatment monitoring rather than relying solely on behavioral observation.

The numbers in context

N=15 ASD, N=9 TD. 65 cannabis-responsive biomarkers. 23 characterized in detail. 40% THC-dominant, 60% CBD-dominant treatment. THC: 0.05-50mg, CBD: 7.5-200mg per dose.

How the study worked

Observational pharmacometabolomics study of saliva from 15 ASD children (pre-treatment and at maximal impact) compared with 9 TD controls. 40% received THC-dominant MC, 60% received CBD-dominant MC. Individualized regimens for 1+ year.

What this study cannot tell us

Very small sample without placebo control. Individualized treatment prevents standardized comparison. Biomarker shifts correlate with behavioral improvement but cannot prove causation. Observational design. Results need replication in larger trials.

How to read the evidence

Small observational study establishing biomarker discovery. Requires validation in larger controlled trials.

When this study was published

Published in 2023.

The bigger picture

This companion paper to the lipidomics study (RTHC-04937) from the same group adds metabolomics data to build a more complete picture of how cannabis affects ASD biology at the molecular level. The convergence of both approaches strengthens the biomarker concept.

Questions still open

Could these biomarkers be validated in a placebo-controlled ASD cannabis trial?
Do THC-dominant and CBD-dominant treatments produce different biomarker profiles?

Common questions

Can saliva metabolomics track cannabis treatment for autism?

This preliminary study identified 65 metabolite biomarkers that shifted toward typical levels in ASD children on medical cannabis, suggesting saliva could be used for objective treatment monitoring.

Which biomarkers changed most in ASD children on cannabis?

N-acetylaspartic acid, spermine, and dehydroisoandrosterone 3-sulfate were highlighted because they have been previously linked to ASD behavioral symptoms.

Read the original research

Cannabis-Responsive Biomarkers: A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder.

Cannabis and cannabinoid research, 8(1), 126-137

View on PubMed ↗Publisher’s paper ↗

Citation

Siani-Rose, Michael; Cox, Stephany; Goldstein, Bonni; Abrams, Donald; Taylor, Myiesha; Kurek, Itzhak. (2023). Cannabis-Responsive Biomarkers: A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder.. Cannabis and cannabinoid research, 8(1), 126-137. https://doi.org/10.1089/can.2021.0129